Biotech Values

[poorgradstudent]

I realize that these are large trials that, by their sheer size, likely balance the arms evenly for multiple factors.

However, with cardiovascular disease being a very multi-modality disease with a great heterogeneity, I'm not convinced that one could properly assess true cardiovascular risk in these trials without prospectively balancing the arms based on cardiovascular risk factors.

It would be sad if Celebrex was also pulled off the market. I think the true risks to the population at large are being exaggerated. I place the odds of Celebrex staying on the market at 95%. 5% chance of it being removed because I fear the irrational judgment of the masses,